Pramiconazole
From Wikipedia, the free encyclopedia
|
Pramiconazole
|
|
| Systematic (IUPAC) name | |
| 1-[4-[4-[4-[[(2R,4S)-2-(2,4-Difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-3-propan-2-ylimidazolidin-2-one | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C35H39F2N7O4 |
| Mol. mass | 659.725 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Pramiconazole is a triazole antifungal undergoing research for the treatment of acute skin and mucosal fungal infections.
It is developed by Barrier Therapeutics.
|
|||||||||||||||||

